All In Biotech

Drug Trial Radar · NCT04530110

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

499

Actual

Start

Sep 16, 2020

Primary completion

Aug 15, 2025

Study completion Dec 22, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab. The total duration of the study is planned to be up to 84 months.

Conditions

  • Migraine

Interventions

  • FremanezumabDrug

    Participants weighing ≥ threshold will receive Dose A subcutaneously monthly. Participants weighing \< threshold will receive Dose B subcutaneously monthly. Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Day 1 up to Day 393
  2. Number of Participants With Potentially Clinically Significant Abnormal Laboratory (Serum Chemistry, Hematology, Coagulation, and Urinalysis) ResultsTime frame: Day 1 up to Day 253
  3. Number of Participants With Shift From Baseline to Last Assessment in Electrocardiogram (ECG) Findings (Assessed by Investigator)Time frame: Baseline to last assessment (up to Day 253)
  4. Number of Participants With Shift From Baseline to Last Assessment in ECG Findings (Assessed by Cardiologist)Time frame: Baseline to last assessment (up to Day 253)
  5. Number of Participants With Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: Day 1 up to Day 253
  6. Number of Participants With Shift From Baseline to Last Assessment in Physical Examination FindingsTime frame: Baseline to last assessment (up to Day 393)
  7. Number of Participants With Suicidal Ideation or Behavior, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Day 1 up to Day 393

Locations

70 sites in 9 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 14319

    Aurora, Colorado

  • Teva Investigational Site 14368

    Colorado Springs, Colorado

  • Teva Investigational Site 14244

    Jacksonville, Florida

  • Teva Investigational Site 14325

    Miami, Florida

  • Teva Investigational Site 14250

    West Palm Beach, Florida

  • Teva Investigational Site 14255

    West Palm Beach, Florida

  • Teva Investigational Site 14243

    Atlanta, Georgia

  • Teva Investigational Site 14258

    Savannah, Georgia

  • Teva Investigational Site 14263

    Hoffman Estates, Illinois

  • Teva Investigational Site 14245

    Wichita, Kansas

  • Teva Investigational Site 14327

    Louisville, Kentucky

  • Teva Investigational Site 14360

    Covington, Louisiana

  • Teva Investigational Site 14365

    Baltimore, Maryland

  • Teva Investigational Site 14246

    Waltham, Massachusetts

  • Teva Investigational Site 14251

    Ann Arbor, Michigan

  • Teva Investigational Site 14270

    Minneapolis, Minnesota

  • Teva Investigational Site 14376

    Ridgeland, Mississippi

  • Teva Investigational Site 14256

    Bridgeton, Missouri

  • Teva Investigational Site 14371

    New Brunswick, New Jersey

  • Teva Investigational Site 14276

    Amherst, New York

  • Teva Investigational Site 14377

    Durham, North Carolina

  • Teva Investigational Site 14248

    Raleigh, North Carolina

  • Teva Investigational Site 14264

    Cincinnati, Ohio

  • Teva Investigational Site 14257

    Oklahoma City, Oklahoma

  • Teva Investigational Site 14363

    Tulsa, Oklahoma

  • Teva Investigational Site 14364

    Philadelphia, Pennsylvania

  • Teva Investigational Site 14374

    Bristol, Tennessee

  • Teva Investigational Site 14252

    Austin, Texas

  • Teva Investigational Site 14273

    Austin, Texas

  • Teva Investigational Site 14367

    Dallas, Texas

  • Teva Investigational Site 14375

    Salt Lake City, Utah

  • Teva Investigational Site 14323

    Norfolk, Virginia

  • Teva Investigational Site 11182

    Ottawa, Ontario, Canada

  • Teva Investigational Site 11179

    Ottawa, Ontario, Canada

  • Teva Investigational Site 11181

    Montreal, Quebec, Canada

  • Teva Investigational Site 40053

    Helsinki, Finland

  • Teva Investigational Site 40049

    Kuopio, Finland

  • Teva Investigational Site 40054

    Oulu, Finland

  • Teva Investigational Site 40052

    Tampere, Finland

  • Teva Investigational Site 32728

    Bad Homburg, Germany

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.